miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

If the AI Bubble Bursts as the Dot-Com Did, History Says the QQQ Might Not Recover Until 2042

View original at fool.com
Motley Fool - Stock Analysis Title: If the AI Bubble Bursts as the Dot-Com Did, History Says the QQQ Might Not Recover Until 2042 Date: 2026-09-20 20:00 Source: https://www.fool.com/investing/2026/09/20/if-the-ai-bubble-bursts-as-the-dot-com-did-history-says-the-qqq-might-not-recover-until-2042/?source=iedfolrf0000001…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Investors should consider the bubble-burst scenario before allocating too much of a portfolio to QQQ given its heavy exposure to the AI megatrend

    60% confidence

  • If the AI bubble were to burst similarly to the dot-com bubble within the next year, the Invesco QQQ might not recover until 2042

    60% confidence

  • The author is not predicting an AI bubble burst and remains bullish on AI and the Nasdaq-100

    60% confidence

  • It took the Nasdaq 15 years to recover its prior peak after the dot-com bust

    60% confidence

Data points we hold from this source

NASDAQ · recovery time from prior peak15 years
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
If the AI Bubble Bursts as the Dot-Com Did, History Says the QQQ Might Not Recover Until 2042 — Source | Via News | es.VIA.NEWS